<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
TATVA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Tatva Chintan Pharma Chem filed its annual initial disclosure with BSE and NSE on April 29, 2025, as required under SEBI's Large Corporate framework. The company confirmed it does NOT qualify as a Large Corporate based on the applicability criteria. Its outstanding borrowings as on March 31, 2025 stood at just Rs. 0.64 crores, which is well below the threshold. The company holds a CRISIL A-/Negative long-term rating and CRISIL A2+ short-term rating from CRISIL Ratings Limited. Since it is not classified as a Large Corporate, the fine/exchange provision is marked Not Applicable. This is a routine annual compliance filing submitted within 30 days of the start of FY 2025-26.
This is a routine regulatory compliance disclosure with no material impact on shareholders. The company's very low debt levels (Rs. 0.64 crores) keep it outside the Large Corporate bracket, meaning it has no mandatory obligation to raise funds through debt securities.